Juvenile idiopathic arthritis coexisting with sickle cell disease: two case reports.
Two cases of coexisting juvenile idiopathic arthritis (JIA) and sickle cell disease (ages 7 and 17) are presented. The diagnoses of JIA were delayed for years because of the similarity of presentations in the two conditions. Both cases had been treated with non-steroidal anti-inflammatory drugs for years. Both had positive rheumatoid factor, and elevated erythrocyte sedimentation rate (ESR) while one of the patients had elevated serum ferritin and anticyclic citrullinated protein. Radiology showed marked arthritic changes with presence of avascular necrosis in a patient's head of femur. Both cases were treated with etanercept for 6 months each, as well as methotrexate. At the end of 6 months, the joint count for pains and swelling were done as well as ESR.
Department of Rheumatology, Olabisi Onabanjo University, Sagamu, Nigeria. femiadelowo2003@yahoo.com
Olufemi
O
Adelowo
Adebayo Samuel
AS
Edunjobi
D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D001323:Autoantibodies / Q000097:blood; D001799:Blood Sedimentation; D002648:Child; D000068800:Etanercept; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012217:Rheumatoid Factor / Q000097:blood
D018501:Antirheumatic Agents; D001323:Autoantibodies; D007074:Immunoglobulin G; D010456:Peptides, Cyclic; D018124:Receptors, Tumor Necrosis Factor; C487763:cyclic citrullinated peptide; D005293:Ferritins; D012217:Rheumatoid Factor; D000068800:Etanercept; D008727:Methotrexate